Results 201 to 210 of about 102,682 (267)

Synthetic Toll‐Like Receptors for Control of Innate Immunity With Far‐Red Light

open access: yesAdvanced Science, EarlyView.
Synthetic Toll‐like receptors (TLRs) are engineered by replacing their natural sensing regions with a far‐red‐light‐responsive module from a bacterial phytochrome. These synthetic receptors enable light‐controlled regulation of immune signaling in mammalian cells.
Anna V. Leopold, Vladislav V. Verkhusha
wiley   +1 more source

Engineering Immunoregenerative Therapy via an Immunomodulatory Binary Pharmacology Hydrogel Depot for Prolonged Allograft Survival

open access: yesAdvanced Science, EarlyView.
An immunomodulatory hydrogel (iGEL) forms spontaneously upon subcutaneous injection, acting as a tissue‐adhesive depot. It releases anti‐rejection and regenerative agents in response to inflammation, suppressing T‐cell activity, promoting vascular repair, and restoring allograft function without systemic immunosuppression.
Ning Wang   +14 more
wiley   +1 more source

Atomic Defects in Layered Transition Metal Dichalcogenides for Sustainable Energy Storage and the Intelligent Trends in Data Analytics

open access: yesAdvanced Science, EarlyView.
This review comprehensively summarizes the atomic defects in TMDs for their applications in sustainable energy storage devices, along with the latest progress in ML methodologies for high‐throughput TEM data analysis, offering insights on how ML‐empowered microscopy facilitates bridging structure–property correlation and inspires knowledge for precise ...
Zheng Luo   +6 more
wiley   +1 more source

RBM10 Deficiency Promotes Anti‐PD‐1 Resistance in LUAD via STING Alternative Splicing‐Driven CCL7 Signaling and Macrophage Polarization

open access: yesAdvanced Science, EarlyView.
RBM10 deficiency promotes anti‐PD‐1 resistance in lung adenocarcinoma by altering STING alternative splicing, which enhances CCL7 secretion and CCR2‐dependent M2 macrophage polarization. A positive feedback loop via mitochondrial transfer sustains this immunosuppression.
Weitong Gao   +14 more
wiley   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

open access: yesAdvanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy